Mental Health Digital Therapeutics Market Size, Share, Trends & Forecast 2026–2034

Detailed Table of Contents — Global Mental Health Digital Therapeutics Market Report 2026–2034

Chapter 1: Introduction

1.1 Report Scope and Market Definition

1.1.1 Mental Health Digital Therapeutics — Definition and Scope

1.1.2 Inclusions and Exclusions (PDT vs OTC DTx, adjacent wellness apps)

1.1.3 Key Assumptions

1.2 Research Objectives

1.3 Market Stakeholders and Target Audience

1.4 Abbreviations and Acronyms

Chapter 2: Research Methodology

2.1 Research Approach Overview

2.2 Primary Research

2.2.1 Stakeholders Consulted (Hospital CIOs, Pharma R&D, Payers, Regulatory Specialists)

2.2.2 Primary Data Collection Process

2.3 Secondary Research

2.3.1 Secondary Sources Reviewed (FDA, BfArM, WHO, JMIR Mental Health, Lancet Digital Health)

2.3.2 Data Extraction and Validation

2.4 Market Sizing and Forecast Methodology

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.4.3 Data Triangulation and Quality Assurance

2.5 Report Limitations and Disclaimers

Chapter 3: Executive Summary

3.1 Global Mental Health Digital Therapeutics Market Snapshot

3.2 Key Market Highlights (CAGR, dominant segment, regional leader)

3.3 Dominant Segments at a Glance

3.4 Regional Snapshot

3.5 Competitive Summary

Chapter 4: Market Dynamics (DROC)

4.1 Market Drivers

4.1.1 Rising Global Mental Health Burden and Clinician-Scarcity Bottleneck

4.1.2 Expanding Regulatory Reimbursement Pathways (FDA, DiGA, PMDA)

4.1.3 AI and Adaptive Personalisation of Therapeutic Protocols

4.1.4 Telehealth Infrastructure Normalisation Post-Pandemic

4.2 Market Restraints

4.2.1 Regulatory Fragmentation Across Jurisdictions

4.2.2 Clinical Evidence Requirements and RCT Barrier

4.2.3 Engagement Attrition and the Therapeutic Paradox

4.3 Market Opportunities

4.3.1 Employer-Sponsored Mental Health DTx Programmes

4.3.2 Paediatric and Adolescent Mental Health DTx

4.3.3 Emerging Market Penetration via Public Health Partnerships

4.3.4 Integration with Pharmacotherapy — Companion Diagnostic DTx

4.4 Market Challenges

4.4.1 Data Privacy, HIPAA Compliance, and Cybersecurity Risk

4.4.2 Digital Divide and Equity of Access

4.4.3 Competitive Pressure from Adjacent Consumer Wellness Platforms

Chapter 5: Mental Health Digital Therapeutics Market — By Product Type

5.1 Overview and Segment Comparison

5.2 Software-Based DTx — Market Sizing, Regulatory Status, Forecast 2026–2034

5.3 Device-Based DTx — Market Sizing, Clinical Applications, Forecast 2026–2034

Chapter 6: Mental Health Digital Therapeutics Market — By Therapeutic Area

6.1 Overview and Segment Comparison

6.2 Depression & Anxiety — Market Sizing, Key Products, Forecast

6.3 Substance Use Disorders — Market Sizing, Regulatory Approvals, Forecast

6.4 PTSD & Trauma — Market Sizing, VA Procurement Opportunity, Forecast

6.5 ADHD — Market Sizing, Paediatric Pipeline, Forecast

6.6 Schizophrenia & Psychosis — Market Sizing, Evidence Status, Forecast

6.7 Others — Market Sizing, Emerging Indications, Forecast

Chapter 7: Mental Health Digital Therapeutics Market — By Delivery Platform

7.1 Overview and Segment Comparison

7.2 Mobile Applications — Market Sizing, Consumer & Enterprise Channel, Forecast

7.3 Web-Based Platforms — Market Sizing, Enterprise IT Integration, Forecast

7.4 Wearable Devices — Market Sizing, Biometric Monitoring Applications, Forecast

7.5 VR/AR Solutions — Market Sizing, Clinical Evidence, Forecast

Chapter 8: Mental Health Digital Therapeutics Market — By End User

8.1 Overview and Segment Comparison

8.2 Patients/Consumers — Market Sizing, Direct-to-Consumer Dynamics, Forecast

8.3 Healthcare Providers — Market Sizing, Prescription DTx Adoption, Forecast

8.4 Payers & Employers — Market Sizing, ROI Framework, Forecast

Chapter 9: Regional Analysis

9.1 Global Mental Health Digital Therapeutics Market — Regional Overview

9.2 North America Mental Health Digital Therapeutics Market

9.2.1 North America Market Overview and Regulatory Environment

9.2.2 The U.S. Mental Health Digital Therapeutics Market

9.2.3 Canada Mental Health Digital Therapeutics Market

9.2.4 Mexico Mental Health Digital Therapeutics Market

9.3 Europe Mental Health Digital Therapeutics Market

9.3.1 Europe Market Overview (DiGA Framework, EU MDR)

9.3.2 Germany | 9.3.3 France | 9.3.4 U.K. | 9.3.5 Italy

9.3.6 Spain | 9.3.7 Russia | 9.3.8 BENELUX | 9.3.9 Sweden

9.3.10 Denmark | 9.3.11 Poland | 9.3.12 Austria | 9.3.13 Rest of Europe

9.4 Asia Pacific Mental Health Digital Therapeutics Market

9.4.1 Asia Pacific Market Overview (PMDA, NHC Policy, TGA)

9.4.2 China | 9.4.3 Japan | 9.4.4 India | 9.4.5 South Korea

9.4.6 Australia | 9.4.7 Thailand | 9.4.8 Indonesia | 9.4.9 Vietnam

9.4.10 Malaysia | 9.4.11 Philippines | 9.4.12 Taiwan

9.4.13 Rest of Asia Pacific

9.5 Latin America Mental Health Digital Therapeutics Market

9.5.1 Latin America Market Overview (ANVISA, SUS Programme)

9.5.2 Brazil | 9.5.3 Argentina | 9.5.4 Colombia

9.5.5 Chile | 9.5.6 Peru | 9.5.7 Rest of Latin America

9.6 The Middle East Mental Health Digital Therapeutics Market

9.6.1 The Middle East Market Overview (Vision 2030, DHA Dubai)

9.6.2 GCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman)

9.6.3 Israel | 9.6.4 Turkey | 9.6.5 Iran | 9.6.6 Rest of The Middle East

9.7 Africa Mental Health Digital Therapeutics Market

9.7.1 Africa Market Overview (SAHPRA, WHO EMRO)

9.7.2 South Africa | 9.7.3 Egypt | 9.7.4 Nigeria

9.7.5 Algeria | 9.7.6 Morocco | 9.7.7 Rest of Africa

Chapter 10: Competitive Landscape

10.1 Market Concentration and Fragmentation Analysis

10.2 Competitive Positioning Map (Clinical DTx vs Consumer Wellness Platforms)

10.3 Key Strategies Adopted by Market Leaders

10.4 Mergers, Acquisitions, and Strategic Partnerships (2020–2025)

10.5 New Product Launches and Regulatory Authorisations

Chapter 11: Company Profiles

11.1 Pear Therapeutics — Overview, Products, Market Position, Recent Developments

11.2 Click Therapeutics — Overview, Pipeline, Pharma Partnerships

11.3 Big Health — Overview, NHS Deployment, Employer Channel

11.4 Headspace Health — Overview, Merger with Ginger, Platform Scale

11.5 Spring Health — Overview, Precision Mental Health Model, Employer Base

11.6 Freespira — Overview, Device-Based DTx, VA Contracts

11.7 Otsuka Digital Health — Overview, Digital Medicine Integration

11.8 Novartis AG — Overview, DTx Investment Programme

11.9 Woebot Health — Overview, NLP Platform, Clinical Validation

11.10 Limbix — Overview, Adolescent DTx Focus, Paediatric Pipeline

11.11 Ginger.io — Overview, Pre-Merger Operations, Clinical Data

11.12 Mindstrong Health — Overview, Passive Monitoring Technology

11.13 Cerebral Inc. — Overview, Telehealth-DTx Hybrid Model

11.14 Noom — Overview, Behaviour Change Platform

11.15 Alto Neuroscience — Overview, MDD DTx Pipeline, FDA Authorisation

Chapter 12: Recent Developments and Strategic Moves

12.1 Mergers and Acquisitions (Headspace/Ginger, Pear Therapeutics assets)

12.2 Product Launches and FDA Authorisations (Rejoyn, Freespira expansion)

12.3 Regulatory Approvals and Policy Changes (DiGA Velibra, PMDA guidance)

12.4 Strategic Partnerships and Collaborations (Click/Otsuka, Click/AstraZeneca)

12.5 Investments and Capacity Expansions (Spring Health Series D, Limbix funding)

Chapter 13: Future Outlook and Forecast Summary

13.1 Mental Health Digital Therapeutics Market Size Forecast, 2026–2034

13.2 Segment Forecast Summary (All 4 Dimensions)

13.3 Regional Forecast Summary (All 6 ZMR Regions)

13.4 Scenario Analysis (Conservative 22.3%, Base 25.3%, Optimistic 29.3% CAGR)

13.5 Key Success Factors and Strategic Recommendations

Chapter 14: Appendix

14.1 Research Methodology Detail

14.2 List of Primary Research Participants (anonymised)

14.3 Data Sources (FDA, BfArM, WHO, ClinicalTrials.gov, Company Reports)

14.4 Glossary of Terms (DTx, PDT, SaMD, DiGA, PEPM, TAM, RCT, CBT, NLP)

14.5 About Zion Market Research

List of Tables (Selected)

Table 1: Global Mental Health Digital Therapeutics Market Size, USD Mn, 2019–2034

Table 2: Market Size by Product Type, USD Mn, 2019–2034

Table 3: Market Size by Therapeutic Area, USD Mn, 2019–2034

Table 4: Market Size by Delivery Platform, USD Mn, 2019–2034

Table 5: Market Size by End User, USD Mn, 2019–2034

Table 6: North America Market Size by Country, USD Mn, 2019–2034

Table 7: Europe Market Size by Country, USD Mn, 2019–2034

Table 8: Asia Pacific Market Size by Country, USD Mn, 2019–2034

Table 9: Latin America Market Size by Country, USD Mn, 2019–2034

Table 10: The Middle East Market Size by Country, USD Mn, 2019–2034

Table 11: Africa Market Size by Country, USD Mn, 2019–2034

Table 12: Competitive Landscape — Strategy Matrix, 15 Companies

Table 13: Recent M&A and Partnership Transactions, 2020–2025

Table 14: FDA-Authorised Prescription Digital Therapeutics (Mental Health), 2017–2025

Table 15: Germany DiGA-Reimbursed Mental Health Applications, 2019–2025

List of Figures (Selected)

Figure 1: Global Mental Health Digital Therapeutics Market Size Bar Chart, USD Mn, 2019–2034

Figure 2: Market Share by Product Type, 2025 (Pie Chart)

Figure 3: Market Share by Therapeutic Area, 2025 (Pie Chart)

Figure 4: Market Share by Delivery Platform, 2025 (Bar Chart)

Figure 5: Market Share by End User, 2025 (Donut Chart)

Figure 6: Regional Market Share, 2025 (Horizontal Bar Chart)

Figure 7: DROC Analysis Framework — 2×2 Infographic

Figure 8: Mental Health Digital Therapeutics Market Segmentation Infographic

Figure 9: Regional Coverage Map — 6 ZMR Regions

Figure 10: Competitive Landscape — Key Players Grid

Figure 11: Value Chain Analysis — Foundational, Integration, Application Tiers

Figure 12: FDA DTx Authorisation Timeline, 2017–2025

Figure 13: Global Mental Health Burden vs DTx Penetration Rate, 2025